EPR22-112: Risk of prostate cancer for Metformin versus Sulphonylurea monotherapy in Type 2 Diabetes Mellitus: A propensity score-matched retrospective cohort study

Gary Tse

doi:10.6004/jnccn.2021.7189

EPR22-112: Risk of prostate cancer for Metformin versus Sulphonylurea monotherapy in Type 2 Diabetes Mellitus: A propensity score-matched retrospective cohort study

Gary Tse

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	EPR22-112
Journal	Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	3.5
DOIs	https://doi.org/10.6004/jnccn.2021.7189
Publication status	Published - 31 Mar 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Oncology

Access to Document

10.6004/jnccn.2021.7189

EPR22-112MetvsSUProstateCancerRisk_removed.pdfFinal published version, 93.8 KB

Cite this

@article{a31c023bfefe472dad4b027004a21c69,

title = "EPR22-112: Risk of prostate cancer for Metformin versus Sulphonylurea monotherapy in Type 2 Diabetes Mellitus: A propensity score-matched retrospective cohort study",

keywords = "Oncology",

author = "Gary Tse",

year = "2022",

month = mar,

day = "31",

doi = "10.6004/jnccn.2021.7189",

language = "English",

volume = "20",

pages = "EPR22--112",

journal = "Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press, LLC",

number = "3.5",

}

TY - JOUR

T1 - EPR22-112: Risk of prostate cancer for Metformin versus Sulphonylurea monotherapy in Type 2 Diabetes Mellitus: A propensity score-matched retrospective cohort study

AU - Tse, Gary

PY - 2022/3/31

Y1 - 2022/3/31

KW - Oncology

U2 - 10.6004/jnccn.2021.7189

DO - 10.6004/jnccn.2021.7189

M3 - Article

SN - 1540-1405

VL - 20

SP - EPR22-112

JO - Journal of the National Comprehensive Cancer Network

JF - Journal of the National Comprehensive Cancer Network

IS - 3.5

ER -